MRIdian MRI-Guided Radiation Therapy
On July 17, 2023, ViewRay announced the filing of a petition for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code. For more information on ViewRay’s restructuring, please click https://cases.stretto.com/ViewRay
MRIdian Treatment Momentum
The Impact of MRIdian
THIS IS WHAT YOU'VE BEENWAITING FOR
MRIdian is the first MR-guided radiotherapy system with peer-reviewed evidence demonstrating reduced side effects and extended survival by decreasing treatment volumes and delivering ablative doses. Learn the impact of MRIdian through stories told firsthand by patients and physicians.
Expanding Cancer Care
MORE PATIENTS. MORE PROOF.MORE PROMISE.
After 9 years of clinical use, more than 31,000 patients have been treated on MRIdian. Today, 62 hospitals worldwide have built successful MRIdian programs to expand cancer care with many centers investing in additional systems to meet patient demand. Research how MRIdian offers personalized cancer treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
Discover MRIdian
SEE WHAT YOU'VE BEENMISSING
Traditional imaging technology associated with radiation delivery systems provides limited visualization of soft tissue, causing the use of implanted markers which can shift during treatment. With MRIdian, diagnostic-quality MRI imaging enables precise contouring and real-time tissue tracking and automated beam control to ensure the precise delivery of the dose to the target.